ArticleTherapeutic advances in gastroenterology2026
Clinical associations, outcomes, and therapeutic management of patients with symptomatic sclerosing mesenteritis.
Article in Therapeutic advances in gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sclerosing mesenteritis (SM) is a rare fibroinflammatory disease of unknown etiology that primarily affects the root of the small bowel mesentery. Associated diseases that contribute to or predispose to the development of SM have not been well-documented. Objectives: We aimed to describe the clinical associations of patients diagnosed with symptomatic SM, their clinical features, outcomes, and therapeutic management. Design: We performed a prospective cohort study from 2014 to 2025. Methods: Eligible patients were those aged ≥ 18 years who presented at two tertiary Medical Centers in Greece with SM-specific symptoms after ruling out other causes of abdominal pain and radiographic signs indicative of the Coulier criteria on computed tomography scans ( Results: In total, 55 patients with symptomatic SM were included, of whom 25.5% developed severe intra-abdominal complications, with even fatal outcomes. Colchicine in combination with corticosteroid tapering was the most frequently administered therapy (47.3%). SM improved in most patients after treatment (72.9%). During the disease course, 23.6% of patients were diagnosed with immunoglobulin G4-related disease (IgG4-RD), 9.1% had co-existing systemic autoimmune rheumatic diseases, and 9.1% were diagnosed with an abdominal/pelvic malignancy within 6 months of initial SM presentation. In the remaining cases (58.2%), an association with metabolic syndrome conditions and excessive accumulation of visceral adipose tissue was observed. Conclusion: In this prospective cohort study, we identified a correlation of symptomatic SM with chronic inflammatory diseases. Certain SM cases are probably part of the IgG4 disease spectrum or systemic autoimmune rheumatic diseases. These results should be taken into account when consulting patients with symptomatic SM, as the clinical management, prognosis, and therapeutic approach may differ according to the underlying systemic disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.